Jafron Biomedical Co

Jafron Biomedical Co Debt Growth

The Year-over-Year Debt Growth of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is -0.76 %. In the previous year, Year-over-Year Debt Growth was -27.92 % — a change of -97.28% (higher).

Debt Growth

-0.76 %

YoY

-97.28%

Last updated:

Year-over-Year Debt Growth of Jafron Biomedical Co is 2025 -0.76 % . Year-over-Year Debt Growth of Jafron Biomedical Co was 2024 -27.92 % . It decreases by -97.28% higher compared to the previous year.

The Jafron Biomedical Co Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2018
-22.00 CNY
Jan 1, 2019
-44.34 CNY
Jan 1, 2020
-49.31 CNY
Jan 1, 2021
2,934.42 CNY
Jan 1, 2022
39.06 CNY
Jan 1, 2023
29.65 CNY
Jan 1, 2024
-27.92 CNY
Jan 1, 2025
-0.76 CNY
The Jafron Biomedical Co Debt Growth history
YEARDebt GrowthYoY
-0.76 %-97.28%
-27.92 %-194.15%
29.65 %-24.09%
39.06 %-98.67%
2,934.42 %-6,051.20%
-49.31 %+11.20%
-44.34 %+101.56%
-22.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Year-over-Year Debt Growth of Jafron Biomedical Co is -0.76 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Jafron Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co